DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
0.508
+0.008 (1.60%)
Nov 20, 2024, 4:00 PM EST - Market closed
DBV Technologies Revenue
DBV Technologies had revenue of $1.07M in the quarter ending September 30, 2024, a decrease of -54.81%. This brings the company's revenue in the last twelve months to $12.52M, up 125.54% year-over-year. In the year 2023, DBV Technologies had annual revenue of $15.73M with 224.69% growth.
Revenue (ttm)
$12.52M
Revenue Growth
+125.54%
P/S Ratio
n/a
Revenue / Employee
$119,190
Employees
105
Market Cap
53.27M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
Dec 31, 2019 | 14.71M | 3.52M | 31.49% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Theratechnologies | 84.32M |
Owlet | 78.61M |
Aadi Bioscience | 25.07M |
Prenetics Global | 22.66M |
Shattuck Labs | 6.44M |
Nutriband | 1.80M |
DBVT News
- 9 days ago - DBV Technologies Announces Plan to Implement ADS Ratio Change - GlobeNewsWire
- 14 days ago - DBV Technologies Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe - GlobeNewsWire
- 4 weeks ago - DBV Technologies to Participate in Upcoming ACAAI 2024 Congress - GlobeNewsWire
- 2 months ago - DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial - GlobeNewsWire
- 2 months ago - DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - DBV Technologies S.A. (DBVT) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report - GlobeNewsWire